Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03610581 · ClinicalTrials.gov registry record · Phase 1
Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix
A Phase 1 study, sponsored by Janssen Vaccines & Prevention B.V..
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT03610581 is a Phase 1 study that was terminated before completion, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 9 participants.
The verdict
NCT03610581, a Phase 1 study, was terminated before completion, sponsored by Janssen Vaccines & Prevention B.V..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess safety and reactogenicity of the 3 vaccine regimens.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Ad26.HPV16
- BIOLOGICAL Ad26.HPV18
- BIOLOGICAL MVA.HPV16/18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2018-09-27 |
| Est. Completion | 2020-10-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03610581
The ClinicalTrials.gov registry entry for NCT03610581 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Vaccines & Prevention B.V., which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03610581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03610581 about?
NCT03610581 is a clinical study titled "Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix". The main purpose of this study is to assess safety and reactogenicity of the 3 vaccine regimens.
What is the current status of trial NCT03610581?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2018-09-27. Estimated completion is 2020-10-15.
What interventions are being tested in trial NCT03610581?
The interventions under investigation include: Placebo (BIOLOGICAL), Ad26.HPV16 (BIOLOGICAL), Ad26.HPV18 (BIOLOGICAL), MVA.HPV16/18 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03610581?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.